标题：Benefits of laboratory personalized antiplatelet therapy in patients undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials
作者：Zhang, Yong; Zhang, Pei; Li, Zhan; Du, Juanjuan; Wang, Jiangrong; Tian, Xiuqing; Gao, Mei; Hou, Yinglong
作者机构：[Zhang, Yong; Zhang, Pei; Li, Zhan; Du, Juanjuan; Wang, Jiangrong; Tian, Xiuqing; Gao, Mei; Hou, Yinglong] Shandong Univ, Shandong Prov Qianfoshan Hos 更多
通讯作者地址：[Hou, YL]Shandong Univ, Shandong Prov Qianfoshan Hosp, Dept Cardiol, 16766 Jingshi Rd, Jinan 250014, Shandong, Peoples R China.
关键词：personalized antiplatelet therapy; percutaneous coronary intervention;; platelet function testing; genetic detection; meta-analysis
摘要：Background: The preventive effects of laboratory personalized antiplatelet therapy (PAPT) strategy including genetic detection and platelet function testing (PFT) on major adverse cardiac events (MACEs) and bleeding events in coronary artery disease (CAD) patients undergoing stenting has been extensively studied. Despite that, no clear conclusion can be drawn. In this study, a meta-analysis was performed to explore a more precise estimation of the benefits of laboratory PAPT.; Methods: Randomized controlled trials were identified by the use of search databases such as PubMed, Embase, and Cochrane Controlled Trials Register up to May 2017, and the estimates were pooled.; Results: Fourteen studies including 9497 patients met the inclusion criteria. The laboratory PAPT reduced MACEs risk (risk ratio [RR] 0.58, 95% confidence interval [CI] 0.42-0.80, p = 0.001), stent thrombosis (RR 0.60, 95% CI 0.41-0.87, p = 0.008) and myocardial infarctions (RR 0.43, 95% CI 0.21-0.88, p = 0.02) compared to the non-PAPT group. No statistically significant difference was observed between the two groups regarding cardiovascular death (RR 0.77, 95% CI 0.51-1.16, p = 0.21), bleeding events (RR 0.96, 95% CI 0.81-1.13, p = 0.59) and ischemic stroke (RR 0.81; 95% CI 0.39-1.66, p = 0.57). The preventive effect on MACEs was more significant in patients with high on-treatment platelet reactivity (RR 0.46; 95% CI 0.27-0.80, p = 0.006).; Conclusions: Coronary artery disease patients after stenting could obtain benefits from laboratory PAPT.